Medtronic, Inc.

Mallinckrodt, Inc.

Piramal Critical Care, Inc.

Fun Gunz Inc.

Thomas R Prentice

John J Foster

Warren L Starkebaum

Kenneth Timothy Heruth

Mark A Christopherson

Mark S Lent

Lynn M Otten

Allan R Markert

Stanley D Harpstead

Angela A Strantz

According to the subject invention, there is disclosed, a dosage and packaging configuration which includes the use of color-coded pre-filled syringes and vials to fill and refill infusion systems with existing and new dosage forms of intrathecal baclofen.

Intrathecal baclofen pharmaceutical dosage forms and related delivery system

The present disclosure relates generally to a pharmaceutical solution comprising hydromorphone or a pharmaceutically acceptable salt thereof that is substantially free of buffer and optionally one or more other additives. The pharmaceutically acceptable salt may be hydromorphone hydrochloride. Also disclosed are methods for the manufacture and use of the solution.

Intrathecal hydromorphone solutions having improved stability

The present invention relates generally to a sterile, particulate-free, stable intrathecal baclofen solution with less than 0.5% of 4-(4-chlorophenyl)-2-pyrrolidone, a degradation product. These solutions are stable under a variety of storage conditions and for extended periods of time. Also disclosed are methods for preparing such compositions.

Intrathecal baclofen pharmaceutical dosage forms with fewer degradation products

The present invention relates generally to a sterile hydromorphone hydrochloride solution that is substantially free of buffer.

Stability of hydromorphone hydrochloride solutions

The invention provides methods and devices to treat obesity by ablating tissue from an exterior surface of a stomach of a patient. For example, the invention may involve ablation of exterior stomach tissue to alter gastric myoelectric activity or muscle function from the exterior surface of the stomach to produce abnormal gastric peristalsis without damaging the mucosal lining of the stomach. The invention may further provide methods and devices to monitor the gastric myoelectric activity before and after the ablation procedure.

Ablation of exterior of stomach to treat obesity

The invention provides methods and devices to reduce stomach acid secretion in a patient with a hyper acid condition. For example, the invention may involve ablation of the stomach lining to destroy acid-producing cells. Destroying acid-producing cells may reduce the amount of stomach acid produced and, therefore the amount of acid refluxed in the esophagus. The invention may further provide methods and devices to monitor the esophageal acid level before and after the ablation procedure.

Ablation of stomach lining to reduce stomach acid secretion

An implantable drug delivery device comprising a microencapsulated drug contained within at least one capsule, a carrier fluid that will dissolve the drug when freed from the capsule, a drug releaser for freeing the microencapsulated drug from the capsule, a reservoir in which the carrier fluid dissolves the drug, and an electromechanical pump to convey the dissolved drug to a catheter, through which the drug is delivered to a target site within a patient.

Drug delivery through microencapsulation

An implantable system for infusing a fluid agent and providing electrical stimulation without requiring an implanted pump or implanted source of electrical energy. An implantable housing is fitted with a percutaneous fill port that communicates with a reservoir to hold a fluid agent, such as a drug. An antenna located inside the housing receives radio frequency power signals from an outside antenna. A pulse generator outside the housing receives power and information from the radio frequency signals to produce stimulation pulses. The pulses and the fluid agent are both transported by a catheter to a site of application in the body. A connector allows the stimulation pulses and fluid agent to be transported from the housing to the catheter while maintaining electrical isolation between the stimulating pulses and the fluid agent.

Growing community of inventors

Lake Elmo, MN, United States of America

Thomas R Prentice